Rationale and evidence for extended infusion of piperacillin-tazobactam

American Journal of Health-System Pharmacy

Volumn 68, Issue 16, 2011, Pages 1521-1526

  Kaufman, Scott E ^a,b   Donnell, Robert W ^c   Hickey, W Scott ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Mercy Medical Center   (United States)

^c Mercy Medical Center ^*  (United States)

Author keywords

Bacterial infections; Beta lactamase inhibitors; Dosage schedules; Drug administration; Hospitals; Injections; Minimum inhibitory concentration; Mortality; Penicillins; Pharmacodynamics; Pharmacoeconomics; Piperacillin; Pseudomonas infections; Tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG SAFETY; HOSPITALIZATION; HUMAN; INFUSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PATIENT CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

EID: 80051912242     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100694     Document Type: Article

References (29)

1. Dellit T.H., Owens R.C., McGowan J.E. Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44:159-177 (Pubitemid 46084814)
2. Arnold A., Brouse S.D., Pitcher W.D. et al. Empiric therapy for gram-negative pathogens in nosocomial and health careassociated pneumonia: Starting with the end in mind. J Intensive Care Med. 2010; 25:259-270
3. Zosyn (piperacillin and tazobactam for injection) package insert. Philadelphia: Wyeth Pharmaceuticals; 2009 Sep.
4. Kim A., Sutherland C.A., Kuti J.L. et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy. 2007; 27:1490-1497 (Pubitemid 350060204)
5. Lodise T.P. Jr, Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007; 44:357-363 (Pubitemid 46147617)
6. Lodise T.P. Jr, Lomaestro B., Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on β-lactam antibiotics: Focus on β-lactam antibioticsInsights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006; 26:1320-1332 (Pubitemid 44306892)
7. DiPiro J.T., Spruill W.J., Wade W.E. et al. Concepts in clinical pharmacokinetics. 5th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2010:1.
8. Drusano G.L. Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug.' Nat Rev Microbiol. 2004; 2:289-300. (Pubitemid 39490099)
9. Craig W.A. . Pharmaco kinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10.
10. Gilbert DN, Moellering RC, Eliopoulos GM et al., eds. The Sanford guide to antimicrobial therapy. 40th ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2010:83.
11. Rodvold K.A. Pharmacodynamics of antiinfective therapy: Taking what we know to the patient's bedside. Pharmacotherapy. 2001; 21(11, suppl):319S-330S. (Pubitemid 33043112)
12. Lacy M.K., Nicolau D.P., Nightingale C.H. et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27:23-27 (Pubitemid 28334413)
13. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998; 27:33-39 (Pubitemid 28334415)
14. Owens R.C., Shorr A.F. Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies. Am J Health-Syst Pharm. 2009; 66(suppl 4):S23-S30
15. Ambrose P.G., Bhavnani S.M., Rubino C.M. et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis. 2007; 44:79-86. [Erratum, Clin Infect Dis. 2007; 44:624.] (Pubitemid 44968990)
16. Patel G.W., Patel N., Lat A. et al. Outcomes of extended infusion piperacillin/ tazobactam for documented gramnegative infections. Diagn Microbiol Infect Dis. 2009; 64:236-240
17. Shea K.M., Cheatham S.C., Smith D.W. et al. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokineticdata from hospitalized patients. Ann Pharmacother. 2009; 43:1747-1754
18. Shea K.M., Cheatham S.C., Wack M.F. et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents. 2009; 34:429-433
19. Lexi-Comp, Inc. Piperacillin and tazobactam sodium: drug information. www.uptodate.com.
20. Ambrose P.G., Owens R.C. Jr, Garvey M.J. et al. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother. 2002; 49:445-453 (Pubitemid 34223665)
21. Pier G.B., Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2010:2835-2860
22. Piperacillin/tazobactam. Medical Letter. 1994; 36(914):7-9.
23. Grant E.M., Kuti J.L., Nicolau D.P. et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillintazobactam program in a large community teaching hospital. Pharmacotherapy. 2002; 22:471-483 (Pubitemid 34270031)
24. Albany Medical Center. About us. www.amc.edu/About%20Us/index.html (accessed 2011 May 2).
25. Kim M.K., Xuan D., Quintiliani R. et al. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother. 2001; 48:259-267 (Pubitemid 32755289)
26. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med. 2005; 171:388- 416.
27. Abbo L. Antimicrobial stewardship activities for the Jackson Memorial Hospital/ University of Miami. www.cdc.gov/ getsmart/healthcare/improve-efforts/ stories.html (accessed 2011 May 2).
28. Xamplas R.C., Itokazu G.S., Glowacki R.C. et al. Implementation of an extendedinfusion piperacillin-tazobactam program at an urban teaching hospital. Am J Health-Syst Pharm. 2010; 67:622-628
29. Sarubi C. Implementation of a new extended-infusion piperacillin/ tazobactam protocol at UCSD Medical Center. www.sdshp.cshp.org/uploads/ informular y/Informulary-Vol-2- Issue%206.pdf (accessed 2011 May 2).